Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belapectin for prevention of esophageal varices in NASH cirrhosis
2019-001983-31Phase 2Active
- Sponsor
- Galectin Therapeutics
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belapectin in Cirrhosis and Portal Hypertension (PH) (3 arms), sponsored by Galectin Therapeutics. Primary endpoint: Proportion of patients in the belapectin treatment. Started Aug 2020; status: active.
02
Drugs
belapectin
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on 2019-001983-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001983-31.